Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.42 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.42 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13097253 | 0.90 | SLC2A1 (0.41) | CYP2C9LNPEP | |
| SCHEMBL17304261 | 0.84 | LNPEP (0.53) | LNPEP | |
| SCHEMBL9278063 | 0.83 | CYP2C9 (0.45) | CYP2C9PARP15PARP10LNPEPPARP2 | |
| SCHEMBL19076086 | 0.83 | LNPEP (0.53) | LNPEP | |
| Hydrochloric Acid SCHEMBL9128720 | 0.82 | CYP2C9 (0.44) | CYP2C9PARP15PARP10LNPEPPARP2 | |
| SCHEMBL2378999 | 0.79 | PARP15 (0.44) | CYP2C9PARP15PARP10PARP2SLC6A2 | |
| SCHEMBL9129980 | 0.78 | LNPEP (0.44) | CYP2C9PARP15PARP10LNPEPPARP2 | |
| SCHEMBL12247660 | 0.77 | MAOA (0.46) | CYP2C9PARP15PARP10PARP2SLC6A2 | |
| SCHEMBL22918690 | 0.76 | NOS3 (0.52) | PARP15PARP10PARP2SLC6A2SLC6A4 | |
| SCHEMBL19405930 | 0.76 | PARP15 (0.44) | CYP2C9PARP15PARP10PARP2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0449940-B1 | NEW THERAPEUTICALLY ACTIVE COMPOUND AND A PROCESS FOR ITS PREPARATION | HAESSLE AB (SE) | 1995-09-13 | — | — | EP | claimed |
| US-5039808-A | Chemical intermediate for antisecretory agent | AKTIEBOLAGET HASSLE (SE) | 1991-08-13 | — | — | US | claimed |
| WO-1990006925-A1 | NEW THERAPEUTICALLY ACTIVE COMPOUND AND A PROCESS FOR ITS PREPARATION | Aktiebolaget Hässle (SE) | 1990-06-28 | — | — | WO | claimed |
| EP-0449940-B1 | NEW THERAPEUTICALLY ACTIVE COMPOUND AND A PROCESS FOR ITS PREPARATION | HAESSLE AB (SE) | 1995-09-13 | — | — | EP | disclosed |
| US-5441968-A | Therapeutically active fluoro substituted benzimidazoles | AKTIEBOLAGET HASSLE (SE) | 1995-08-15 | — | — | US | disclosed |
| US-5274099-A | A mixture of 5- and 6-fluoro-2-(((4-cyclopropylmethoxy-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole-1-yl methyl ethyl carbonate | AKTIEBOLAGET HASSLE (SE) | 1993-12-28 | — | — | US | disclosed |
| EP-0506759-A1 | THERAPEUTICALLY ACTIVE FLUORO SUBSTITUTED BENZIMIDAZOLES, PROCESSES FOR THEIR PREPARATION AS WELL AS THEIR USE | AKTIEBOLAGET HÄSSLE (SE) | 1992-10-07 | — | — | EP | disclosed |
| US-5049674-A | Antiulcer | AKTIEBOLAGET HASSLE (SE) | 1991-09-17 | — | — | US | disclosed |
| US-5039808-A | Chemical intermediate for antisecretory agent | AKTIEBOLAGET HASSLE (SE) | 1991-08-13 | — | — | US | disclosed |
| WO-1991009028-A1 | THERAPEUTICALLY ACTIVE FLUORO SUBSTITUTED BENZIMIDAZOLES, PROCESSES FOR THEIR PREPARATION AS WELL AS THEIR USE | Aktiebolaget Hässle (SE) | 1991-06-27 | — | — | WO | disclosed |
| US-5008278-A | 5-fluoro-2 (4-cyclopropylmethoxy-2-pridinyl)-methyl! sulfinyl!-1h-benzimidazole for inhibiting gastric acid secretion | AKTIEBOLAGET HASSLE (SE) | 1991-04-16 | — | — | US | disclosed |
| WO-1990006925-A1 | NEW THERAPEUTICALLY ACTIVE COMPOUND AND A PROCESS FOR ITS PREPARATION | Aktiebolaget Hässle (SE) | 1990-06-28 | — | — | WO | disclosed |